Title: Combat Methamphetamine Epidemic Act of 2005
Content: ephedrine ; pseudoephedrine ; phenylpropanolamine (no longer OTC due to a proposed increased risk of stroke in younger women) The Combat Methamphetamine Epidemic Act of 2005 (CMEA) is federal legislation enacted in the United States on March 9, 2006, to regulate, among other things, retail over-the-counter sales of following products because of their use in the manufacture of illegal drugs: Retail provisions of the CMEA include daily sales limits and 30-day purchase limits, placement of product out of direct customer access, sales logbooks, customer ID verification, employee training, and self-certification of regulated sellers. The CMEA is found as Title VII of the USA PATRIOT Improvement and Reauthorization Act of 2005 (H.R. 3199). The last provisions of the law took effect on 30 September 2006.
Title: Methamphetamine in the United States
Content:  needs of smaller and mid-sized communities to deal with the crisis, and develop prevention, treatment and interdiction strategies for meth which can then be applied to cities of all sizes as the methamphetamine crisis spreads across the nation." As a result of the U.S. Combat Methamphetamine Epidemic Act of 2005 (CMEA), which was passed as an amendment to the renewal of the USA PATRIOT Act, there are restrictions on the amount of pseudoephedrine and ephedrine one may purchase in a specified time period and further requirements that these products must be stored in order to prevent theft. "The CMEA requires record-keeping and identification of all sales and reports to law 
Title: Pseudoephedrine
Content:  way around the new regulations. Congress passed the Combat Methamphetamine Epidemic Act of 2005 ("CMEA") as an amendment to the renewal of the USA Patriot Act. Signed into law by president George W. Bush on March 6, 2006, the act amended, concerning the sale of pseudoephedrine-containing products. The law mandated two phases, the first needing to be implemented by April 8, 2006, and the second to be completed by September 30, 2006. The first phase dealt primarily with implementing the new buying restrictions based on amount, while the second phase encompassed the requirements of storage, employee training, and record keeping. Though the law was 
Title: Jim Talent
Content:  Talent cosponsored the Combat Meth Act with Sen. Dianne Feinstein (D-CA). The legislation, which was attached to the reauthorization of the USA Patriot Act, passed on March 2, 2006 and restricts the sale of products necessary to produce methamphetamines. President Bush signed the act into law on March 9, 2006. As a result of the act, certain cold medicines are only to be made available behind the counter and the amount of such medicines that can be purchased by one person is limited.
Title: Montana Meth Project
Content:  In November 2006, the Office of National Drug Control Policy (ONDCP) published a report, Pushing Back Against Meth: A Progress Report on the Fight, highlighting the impact of recently enacted State and Federal laws, such as the Combat Methamphetamine Epidemic Act (CMEA) of 2005, that restricted transactions for the over the counter drugs that can be used to manufacture methamphetamine. Based on the results of Quest Diagnostics' preliminary review of workplace drug tests conducted during the first five months of 2006, the nationwide adult usage of meth declined by 12% when compared to the same period in 2005. Quest provided state-level results: on the state level, results varied according to the strictness and duration of the states' laws. "Montana’s methamphetamine precursor law went into effect July 
Title: Combat Methamphetamine Epidemic Act of 2005
Content:  Ephedrine, pseudoephedrine, and phenylpropanolamine are precursor chemicals used in the illicit manufacture of methamphetamine or amphetamine. They are also common ingredients used to make cough, cold, and allergy products. It was argued that the CMEA would curtail the clandestine production of methamphetamine. The U.S. Department of Justice claimed that states that had enacted similar or more restrictive retail regulations saw dramatic drops in the numbers of small clandestine labs.
Title: Illicit Drug Anti-Proliferation Act
Content:  The Illicit Drug Anti-Proliferation Act of 2003 is a United States federal law enacted as a rider within the PROTECT Act on April 30, 2003. A substantially similar Act was proposed during the previous Congress as the Reducing Americans' Vulnerability to Ecstasy Act (RAVE Act).
Title: Combat Methamphetamine Epidemic Act of 2005
Content:  not to exceed 3.6 grams without regard to the number of transactions ; 30 day (not monthly) sales limit not to exceed 7.5 grams if sold by mail-order or "mobile retail vendor" ; 30 day purchase limit not to exceed 9 grams of pseudoephedrine base in regulated products (misdemeanor possession offense under 21 USC 844a for the individual who buys it) ; Prescriptions are exempt from logbook requirements. "The CMEA requires record-keeping and identification of all sales and reports to law enforcement of any 'suspicious' transactions. Purchasers are limited to '3.6 grams of pseudoephedrine base' per day and 9 grams per month. (Buying more than that is a federal misdemeanor.)" The statute also includes the following requirements for merchants who sell these products:
Title: Methamphetamine in the United States
Content:   Methamphetamine in the United States is regulated under Schedule II of the Controlled Substances Act. It is approved for pharmacological use in the treatment of attention deficit hyperactivity disorder and treatment-resistant obesity, but it is primarily used as a recreational drug. In 2012, 16,000 prescriptions for methamphetamine were filled, approximately 1.2 million Americans reported using it in the past year, and 440,000 reported using the drug in the past month. Much of the methamphetamine consumed in the US is manufactured domestically by amateur chemists in meth labs from common household drugs and chemicals such as lye, lithium, and ammonia. Since the passage of the Combat Methamphetamine Epidemic 
Title: Illinois Methamphetamine Precursor Control Act
Content:  The Methamphetamine Precursor Control Act (MPCA, ) is an Illinois state law that was signed into law on November 16, 2005, and took effect on January 15, 2006. The MPCA is an act used to create significant barriers such as the requirement to present ID to purchase cold medication that contains pseudoephedrine (Sudafed, Tylenol Cold and Claritin D) which could be used to produce methamphetamine. This is one of many state laws regulating the supply of pseudoephedrine that preceded the federal Combat Methamphetamine Epidemic Act of 2005. The Act was introduced as Senate Bill 273.

Question: In what country is Combat Methamphetamine Epidemic Act of 2005?
Answer: United States of America.
the United States of America.
America.
U.S.A.
USA.
U.S.
US.
the US.
the USA.
US of A.
the United States.
U. S. A.
U. S.
the States.
the U.S.
'Merica.
U.S.
United States.
'Murica.